Véronique Hentgen

Véronique Hentgen

Auto-generated profile, based on publicly available information

Véronique Hentgen

Center Hospitalier de Versailles, Le Chesnay, France

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2025 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
SOSeza Ozen
Seza Ozen
ESErdal Sag
Erdal Sag
TOTeresa Oton
Teresa Oton
AGAhmet Gül
Ahmet Gül
CSCristiana Sieiro Santos
Cristiana Sieiro Santos
LCLoreto Carmona
Loreto Carmona
Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease despite being a rare disease for many rheumatologists. These evidence-based recommendations update the ones issued in 2016 to account for the recent developments in the field and aim to guide rheumatologists and other health professionals in the treatment and follow-up of patients with FMF. A multidisciplinary panel was assembled, including rheumatologists, internists, paediatricians, a nephrologist, an occupational therapist, a physiotherapist, 2 methodologists, and 2 patient representatives, all from the Eastern Mediterranean area and Europe. Several systematic reviews were performed on the pharmacological treatment of FMF and its complications. The previous recommendations were revised considering the updated evidence, and the new levels of evidence were incorporated. The agreement with the recommendations was obtained through a Delphi survey. The final set comprises 4 overarching principles and 12 recommendations, each presented with its degree of agreement (0-10), level of evidence, and rationale. The degree of agreement was greater than 9/10 in all instances, and the level of evidence improved in most updated statements. Improving adherence is emphasised as an important aspect in several statements. These new recommendations include a priority set, quality indicators, and other suggested implementation strategies. This article presents a set of widely accepted recommendations for treating and monitoring FMF, supported by the best available evidence and expert opinion. These recommendations are valuable for guiding physicians in caring for patients with FMF.

19 December 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
IEInès Elhani
Inès Elhani
QRQuentin Riller
Quentin Riller
GBGuilaine Boursier
Guilaine Boursier
VHVéronique Hentgen
Véronique Hentgen
FRFrédéric Rieux-Laucat
Frédéric Rieux-Laucat
SGSophie Anne Georgin-Lavialle
Sophie Anne Georgin-Lavialle

30 April 2022 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
IEInès Elhani
Inès Elhani
VHVéronique Hentgen
Véronique Hentgen
GGGilles Grateau
Gilles Grateau
SGSophie Anne Georgin-Lavialle
Sophie Anne Georgin-Lavialle

9 April 2025 in European Journal of Internal Medicine
Verified
Journal Article
Open access
IEInès Elhani
Inès Elhani
LCLaure Calas
Laure Calas
FBFarah Bejar
Farah Bejar
BFBruno Fautrel
Bruno Fautrel
LPLaurence Pieroni
Laurence Pieroni
SGSophie Anne Georgin-Lavialle
Sophie Anne Georgin-Lavialle
Auto-inflammatory diseases (AIDs) are characterized by excessive activation of innate immunity. Current biomarkers, such as C-reactive protein (CRP) and serum Amyloid A (SAA), are not disease-specific and cannot reflect disease severity. Interleukin-18 (IL-18), a pro-inflammatory cytokine of the IL-1 superfamily, has been recently studied as, biomarker for AIDs; This study aims to evaluate total serum IL-18 levels in a large cohort of AID patients from the adult French national reference center for AID. We conducted a retrospective analysis of 708 IL-18 measurements from 516 patients. The highest IL-18 levels were observed in diseases involving the pyrin inflammasome, such as Familial Mediterranean fever, mevalonate kinase deficiency, CDC42-associated AID and PSTPIP1-associated AID. Receiver operating characteristic (ROC) curve analysis demonstrated an AUC of 0.87 for IL-18, with a sensitivity of 83.4 % and specificity of 76.2 % at a cut-off value of 412 pg/mL, in differentiating pyrin inflammasome-related diseases from other monogenic inflammatory diseases. Our findings suggest the utility of total serum IL-18 as a diagnostic tool, particularly for pyrin inflammasome-related AIDs, that could in the future help to personalized treatment strategies.

8 April 2024 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
IKIsabelle Koné-Paut
Isabelle Koné-Paut
SGSophie Georgin-Lavialle
Sophie Georgin-Lavialle
ABAlexandre Belot
Alexandre Belot
MJMagali Jover
Magali Jover
MPMathilde Pouriel
Mathilde Pouriel
VHVéronique Hentgen
Véronique Hentgen
Background: Our study aimed to provide real-world evidence on the treatment patterns, effectiveness and safety of canakinumab in France in Familial Mediterranean Fever (FMF), Mevalonate Kinase Deficiency (MKD), and Tumor necrosis factor Receptor Associated Periodic Syndrome (TRAPS). Methods: This study used the JIR cohort, a multicentre international registry created in 2013 to collect data on patients with juvenile inflammatory rheumatic diseases. French patients diagnosed with FMF, MKD or TRAPS and treated with canakinumab were included in this study. Results: 31 FMF, 26 MKD and 7 TRAPS patients received canakinumab during the study period. Most of them initiated canakinumab at the recommended dose of 2 mg/kg or 150 mg, but less than half of FMF and MKD patients initiated it at the recommended frequency (every 4 weeks). Two years after initiation, the rate of patients still on treatment was 78.1% in FMF, 73.7% in MKD, and 85.7% in TRAPS patients. While the dose per injection remained globally the same over the course of the treatment, some adjustments of the dose intervals were observed. Six patients had a severe adverse event reported. Of those, three were possibly related to canakinumab. Conclusion: This interim analysis showed a good maintenance of canakinumab treatment 2 years after initiation and confirmed its safety profile in real-life practice in France in patients diagnosed with FMF, MKD and TRAPS. The high variety of dose and interval combinations observed in canakinumab treated patients let suppose that physicians adapt the posology to individual situations rather than a fixed treatment plan.

24 November 2024 in RMD Open
Verified
Journal Article
Open access
PDF file
IEInès Elhani
Inès Elhani
SBStefan Backes
Stefan Backes
TKTilmann Kallinich
Tilmann Kallinich
GAGayane Amaryan
Gayane Amaryan
ABAlexandre Belot
Alexandre Belot
HWHelmut Wittkowski
Helmut Wittkowski
Introduction Familial Mediterranean fever (FMF) is a genetic disease leading to recurrent episodes of inflammation. Two pathogenic variants are required for classical disease, but the disease can occur in heterozygous patients. Patients are treated continuously with colchicine to prevent amyloid A (AA) amyloidosis, including heterozygous patients who display a moderate form of FMF and rarely develop AA amyloidosis. The need for lifelong colchicine treatment in heterozygous FMF is therefore controversial. We aimed to characterise genotype-specific levels of inflammatory biomarkers, and to focus on heterozygous patients who discontinued colchicine. Methods All patients with FMF from the European databases AIDnet and JIRcohort who received colchicine during follow-up were included. Demographics, C reactive protein (CRP), serum amyloid A (SAA), S100A8/A9 and S100A12 levels, leucocyte and neutrophil counts were extracted. Visits were classified as active, subclinical or inactive according to symptoms, CRP and SAA levels. Results Data from 747 patients were extracted (233 homozygous, 201 compound heterozygous, 224 heterozygous patients, 49 heterozygous with one class III variant and 40 compound heterozygous with two class III variants). During active visits, all biomarker levels were higher compared with inactive visits (p<0.001). Heterozygous patients showed lower levels of CRP, SAA, S100A8/A9 and S100A12 during inactive and subclinical visits than patients with two class IV-V variants. Colchicine was discontinued in 52 heterozygous patients and reintroduced in 23 of them (44%). Conclusion S100A8/A9 and S100A12 proteins are biomarkers that can be used to assess disease activity. Heterozygous patients have lower levels of inflammatory biomarkers and some of them can sustainably discontinue colchicine treatment.